上海谊众(688091) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥71,032,214.87, representing a year-on-year increase of 3.39% compared to ¥68,702,991.41 in the same period last year[5] - Net profit attributable to shareholders decreased by 51.38% to ¥14,185,975.54 from ¥29,178,031.68 in the previous year[5] - The basic earnings per share decreased by 61.11% to ¥0.07 from ¥0.18 in the same period last year[5] - Net profit for Q1 2025 was ¥14,185,975.54, a decrease of 51.5% from ¥29,178,031.68 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.07, down from ¥0.18 in Q1 2024[20] Cash Flow - The net cash flow from operating activities was negative at -¥35,461,931.24, a decline of 222.80% compared to ¥28,877,820.51 in the same period last year[5] - Cash flow from operating activities in Q1 2025 was negative at -¥35,461,931.24, compared to a positive cash flow of ¥28,877,820.51 in Q1 2024[22] - Cash inflow from investment activities in Q1 2025 was ¥2,265,244,086.29, significantly higher than ¥327,424,747.27 in Q1 2024[22] - The company reported a net cash outflow from investment activities of -¥13,182,738.71 in Q1 2025, compared to a net inflow of ¥15,609,268.37 in Q1 2024[22] - The net cash flow from financing activities was $2,588,963.52, compared to $8,805,402.79 in the previous period[23] - The net increase in cash and cash equivalents was a decrease of $46,055,706.43, contrasting with an increase of $53,292,491.67 previously[23] - The ending balance of cash and cash equivalents stood at $598,350,982.88, down from $963,178,159.26 at the beginning of the period[23] Research and Development - Research and development expenses totaled ¥9,276,624.21, an increase of 65.78% from ¥5,595,803.86 in the previous year, accounting for 13.06% of revenue[6] - Research and development expenses increased to ¥9,276,624.21 in Q1 2025, compared to ¥5,595,803.86 in Q1 2024, reflecting a growth of 65.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,466,791,387.83, a slight increase of 1.30% from ¥1,447,992,684.90 at the end of the previous year[6] - The total assets of the company are ¥1,466,791,387.83, compared to ¥1,447,992,684.90 at the end of 2024, indicating an increase[15] - The total liabilities as of March 31, 2025, are ¥40,773,311.62, compared to ¥39,446,131.43 at the end of 2024[15] - Total liabilities increased to ¥44,115,058.89 in the latest reporting period, compared to ¥42,971,884.05 previously[16] - The total non-current assets amount to ¥694,171,916.47, an increase from ¥671,785,597.36 at the end of 2024[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,144[10] - The largest shareholder, Zhou Jinsong, holds 40,127,058 shares, representing 19.41% of total shares[10] - The company has a total of 24,703,546 shares held by Shanghai Kaibao Pharmaceutical Co., Ltd., representing 11.95% of total shares[11] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[12] Operational Performance - The company reported a 348% increase in sales volume of its core product, paclitaxel micelles, which was included in the medical insurance list[8] - Total operating revenue for Q1 2025 reached ¥71,032,214.87, an increase of 3.86% compared to ¥68,702,991.41 in Q1 2024[18] - Total operating costs for Q1 2025 were ¥53,585,184.88, up 44.73% from ¥36,997,180.69 in Q1 2024[18] - The company experienced increased costs in raw material procurement, marketing expenses, and R&D investments, impacting overall profitability[8] Equity - Total equity attributable to shareholders rose to ¥1,422,676,328.94 from ¥1,405,020,800.85, indicating a growth of 1.25%[16] Accounting Standards - The company will not apply new accounting standards starting from 2025[23]